These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23326467)

  • 1. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
    Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
    PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
    Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
    J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
    Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
    Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
    Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
    Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
    Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
    J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
    Masuyama J; Murakami T; Iwamoto S; Fujita S
    Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
    Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma.
    Rujkijyanont P; Chan WK; Eldridge PW; Lockey T; Holladay M; Rooney B; Davidoff AM; Leung W; Vong Q
    Cancer Res; 2013 Apr; 73(8):2608-18. PubMed ID: 23440424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
    Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
    Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
    Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
    BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
    Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
    PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
    Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
    Torelli GF; Rozera C; Santodonato L; Peragine N; D'agostino G; Montefiore E; Napolitano MR; Monque DM; Carlei D; Mariglia P; Pauselli S; Gozzer M; Bafti MS; Girelli G; Guarini A; Belardelli F; Foà R
    Blood Transfus; 2015 Jul; 13(3):464-71. PubMed ID: 25761309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
    Lee HR; Son CH; Koh EK; Bae JH; Kang CD; Yang K; Park YS
    Sci Rep; 2017 Sep; 7(1):11075. PubMed ID: 28894091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.